An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available.
Mineralys Therapeutics has completed enrollment ahead of schedule for its Launch-HTN trial, part of a pivotal program evaluating lorundrostat for treating uncontrolled and resistant hypertension. With the trial set to finish earlier than expected, investors can anticipate topline results by mid-2025. The company aims to model real-world treatment scenarios and has received enthusiastic participation from both physicians and patients.
For detailed information about MLYS stock, go to TipRanks’ Stock Analysis page.
